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Abstract 
Problem: The United States has some of the worst maternal mortality and morbidity rates for a 
developed nation and these rates are on the rise, which has profound implications for the well-
being of mothers, their children, and the communities in which they reside. With the incidence of 
preeclampsia of three to five percent, one recommendation for improvement in maternal 
morbidity and mortality is with the standardization of care by providers and bedside nurses when 
caring for patients. With the standardization of care and use of evidence-based protocols, 
maternal health can be improved. 
Aim: The aim of this quality improvement project was to create a protocol for obstetric care 
providers and nurses to use that will improve outcomes for patients diagnosed with preeclampsia 
in a community hospital setting.  The evidence-based practice protocol is designed to enhance 
the care for women in pregnancy and the immediate postpartum period. 
Method: Following a thorough review of the literature, an evidence-based practice protocol was 
developed for a community hospital in Southern Johnson County, Kansas.  This protocol was 
evaluated by both providers and bedside nurses with at least 5 years of obstetric experience using 
a validated and reliable tool for protocol evaluation.  There was an opportunity for participants to 
offer comments and concerns, which was considered for inclusion in a revised protocol. 
Results: After the evaluation of the protocol, comments as well as evaluation ratings were 
considered. A revised protocol was created and presented to practice committees for use at the 
community hospital. 
Keywords: hypertension, preeclampsia, pregnancy, quality improvement, protocol 
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1: Introduction 
Maternal mortality and morbidity are a worldwide concern.  In 2000, the United Nations 
presented the Millennium Development Goals (MDG) which were intended as a health blueprint 
for all countries. Of the eight goals, one was to decrease worldwide maternal mortality and 
morbidity by 75% by 2015 (Jacobsen, 2019). From 2000 to 2014, maternal mortality and 
morbidity trended the opposite direction in the continental United States, while being reduced 
44% worldwide (MacDorman et al., 2016; Jacobsen, 2019). “The well-being of mothers, infants, 
and children determines the health of the next generation and can help predict future public 
health challenges for families, communities, and the medical care system” (Office of Disease 
Prevention and Health Promotion, 2018, para 1). 
The maternal mortality and morbidity rate in the United States is staggering. According 
to the Central Intelligence Agency, the United States ranks 49th out of 184 countries for maternal 
mortality, higher than any other developed country, and it is still on the rise (Central Intelligence 
Agency, 2018). This concerning fact has caught the attention of many influential practice leaders 
in women’s health including the American Congress of Obstetrics and Gynecologists (ACOG), 
American College of Nurse-Midwives (ACNM), Association of Women’s Health, Obstetric, and 
Neonatal Nurses (AWHONN), and the California Maternal Quality Care Collaborative 
(CMQCC). 
The use of protocols, triggers, bundles, and checklists have led to improved outcomes for 
women when implemented to address practice concerns (Arora et al., 2016). The goal of 
implementing an evidenced-based protocol is to improve the outcomes for women, improve the 
readiness of the unit to care for patients at risk for or diagnosed with a complication, and to 
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enable the providers to better recognize the women that are at risk for complications in order to 
make a timely and accurate diagnosis (Bernstein et al., 2016). 
2: Problem and Significance 
Maternal mortality and morbidity are concepts that are often used in conjunction with one 
another and are therefore often combined in the literature and in discussion. Independently, 
maternal mortality is a complicated concept with different terminology used to describe this 
phenomenon. First, there is pregnancy-related death. Pregnancy-related death is universally 
defined as the death of any woman, from any cause, while pregnant or within one calendar year 
of termination of pregnancy (Center for Disease Control [CDC], 2018). In contrast maternal 
death is defined as the death of a woman while pregnant and within 42 days of termination of 
pregnancy (CDC, 2018). The differing definitions that fall under the category of maternal 
mortality may lead to challenges interpreting the rates of mortality. 
Maternal morbidity is more difficult to define because of the lack of a unified reporting 
system and inconsistent terminology (Koblinsky et al., 2012). Maternal morbidity, which refers 
to “any physical or mental illness or disability directly related to pregnancy and/or childbirth” 
(Koblinsky et al., 2012, p. 125), may not be life-threatening but can significantly impact quality 
of life. Maternal morbidity is classified as severe maternal morbidity (SMM) or non-severe 
maternal morbidity, but the literature is not always consistent with these phrases. Despite 
inconsistencies in reporting, there is an increase in severe maternal morbidity by 106% in the last 
decade (Gibson, Rohan & Gillespie, 2017). Morbidities, or obstetric or maternal complications, 
related to preeclampsia include, but are not limited to, increased risk of diabetes and 
hypertension recurrence, increased risk of preeclampsia in future pregnancies, early delivery of 
infant, admission to Intensive Care Unit, renal failure, stroke, respiratory failure, eclampsia, 
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HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome, organ failure, disseminated 
intravascular coagulation, and death (ACOG, 2013; August & Sibai, 2018; Supplee, Bingham, & 
Kleppel, 2017; Sutton, Harper, & Tita, 2018). 
Hypertensive disorders of pregnancy encompass several diagnoses. More than 10% of 
pregnancies are affected by a hypertensive disorder (Sutton, Harper, & Tita, 2018). Classically, 
hypertension is defined as a systolic blood pressure of greater than or equal to 140 mm Hg and/or 
a diastolic blood pressure of greater than or equal to 90 mm Hg (ACOG, 2013). But, 
hypertension may develop during the pregnancy and may lead to maternal morbidity and/or 
mortality. Hypertensive disorders of pregnancy include preeclampsia, eclampsia, gestational 
hypertension, chronic hypertension with superimposed preeclampsia, and HELLP Syndrome. For 
this project, there will be a focus on differentiating gestational hypertension from preeclampsia. 
See Figure 1 for diagnostic criteria for those hypertensive disorders reviewed below.  
Chronic Hypertension • BP of ≥ 140 mm Hg systolic or ≥ 90 mm Hg prior to conception 
• Identified prior to 20 weeks gestation 
• Continues after 12 weeks gestation 
• Use of antihypertensive medications prior to pregnancy 
Preeclampsia • BP of ≥ 140 mm Hg systolic or ≥ 90 mm Hg or higher on 2 occasions 
greater than 4 hours apart 
• Occurring after 20 weeks gestation 
• Proteinuria  
Severe Features of Preeclampsia One or more of the following: 
• BP of ≥ 160 mm Hg systolic or ≥ 110 mm Hg 
• Thrombocytopenia 
• Renal insufficiency 
• Impaired liver function 
• Pulmonary edema 
• Cerebral or visual symptoms 
Chronic Hypertension with 
Superimposed Preeclampsia 
• BP of ≥ 140 mm Hg systolic or ≥ 90 mm Hg 
• Sudden increase or new-onset of proteinuria 
• Worsening of hypertension 
• Any of the severe features of preeclampsia 
Gestational Hypertension • BP of ≥ 140 mm Hg systolic or ≥ 90 mm Hg after 20 weeks gestation 
• No proteinuria or other signs of preeclampsia 
• Resolves by 12 weeks postpartum 
Figure 1. Hypertensive disorders of pregnancy diagnostic criteria table. Adapted from ACOG, 2017. 
BP= Blood pressure, measured in mmHg. 
6 
Preeclampsia is one of the hypertensive disorders of pregnancy and is a common cause of 
maternal morbidity, and occasionally mortality (ACOG, 2013). Preeclampsia is categorized as 
either preeclampsia without severe features or preeclampsia with severe features. Preeclampsia is 
defined as a blood pressure of greater than or equal to 140 mm Hg systolic and/or 90 mm Hg 
diastolic on 2 occasions at least 4 hours apart in a patient in a previously normotensive patient 
that is greater than 20 weeks gestation and proteinuria of greater than or equal to 300 mg per 24-
hour urine collection or protein/creatinine ratio of greater than 0.3 mg/dL. In the absence of 
proteinuria, preeclampsia can also be diagnosed by the patient having thrombocytopenia with 
platelet count of less than 100,000/microliter, serum creatinine concentrations of greater than 1.1 
mg/dL in the absence of other renal disease, elevated blood concentrations of liver transaminases 
to twice normal concentration, pulmonary edema, and/or cerebral or visual symptoms. 
Preeclampsia with severe features is when any of the following criteria are met: (a) blood 
pressure of 160 mm Hg systolic or higher or 110 mm Hg diastolic or higher on two occasions at 
least 4 hours apart while the patient is on bedrest; (b) oliguria with urine output of less than 500 
mL in 24 hours; (c) persistent headache unrelieved by analgesics or with visual disturbances; (d) 
pulmonary edema; (e) epigastric or right upper quadrant pain; (f) impaired liver functions greater 
to or equal to twice the upper limits of normal; (g) thrombocytopenia; or (h) renal insufficiency 
(ACOG, 2013; August & Sibai, 2018; Sutton, Harper, & Tita, 2018). 
Gestational hypertension is defined as hypertension, in the absence of proteinuria, 
beginning after 20 weeks gestation in a pregnant woman. Chronic hypertension is elevated blood 
pressures diagnosed prior to 20 weeks gestation, although this is more accurately diagnosed 
when a patient is not pregnant. Additionally, women that are prescribed, and taking, 
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antihypertensive medications prior to pregnancy are considered to have chronic hypertension. 
Hypertension that continues beyond 12 weeks postpartum is classified as chronic hypertension.   
The final hypertensive disorder of pregnancy is chronic hypertension with superimposed 
preeclampsia. This is diagnosed when a patient with preexisting chronic hypertension develops 
preeclampsia (ACOG, 2013). This is suspected when the woman has a sudden increase in blood 
pressure in a woman with a previously well-controlled blood pressure regardless of use of anti-
hypertensive medication or new onset of proteinuria. This diagnosis has the highest risk of 
adverse outcomes (Sutton et al., 2018). 
Epidemiologic Data 
The leading causes of maternal mortality and morbidity in the United States are 
cardiovascular diseases (15.2%), non-cardiovascular diseases (14.7%), infection or sepsis 
(12.8%), hemorrhage (11.5%), cardiomyopathy (10.3%), thrombotic pulmonary embolism 
(9.1%), cerebrovascular accidents (7.4%), hypertensive disorders of pregnancy (6.8%), amniotic 
fluid embolism (5.5%), anesthesia complications (0.3%) (CDC, 2018). Preeclampsia and 
hypertensive disorders of pregnancy combined complicate five to eight percent of all pregnancies 
(Preeclampsia.org, 2010). The prevalence of preeclampsia is about 3.4% in the United States; 
however, it is 1.5 to 2 times higher in primigravida women (August & Sibai, 2018). Morbidity 
rates are more difficult to discern, but women that experience maternal morbidity are about 20 to 
30 times more likely to die, which is known as maternal mortality (Firoz et al., 2013).   
About half of these causes of maternal mortality and morbidity are preventable, and just 
over half of the maternal deaths occur in the postpartum period (Bingham et al., 2018). Among 
these causes, hypertensive disorders of pregnancy are a preventable cause of maternal mortality 
(Bernstein et al., 2017). Some of the complications that arise from preeclampsia in pregnancy 
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include risk of pre-term birth, cerebral complications, and long-term cardiovascular disease in 
women (Sutton et al., 2018). With the use of an evidenced-based protocol, facilities have been 
able to reduce blood pressures in a timely fashion leading to a decrease in cerebral complications 
(Bernstein et al., 2017). Women that have been diagnosed with preeclampsia are at a greater risk, 
a relative risk of 7.6 times, to have preeclampsia in subsequent pregnancies (Dhariwal & Lynde, 
2018).  
Standardized Policies 
The California Maternal Quality Care Collaborative (CMQCC) is comprised of key 
stakeholders from a variety of healthcare disciplines with one purpose in mind, improve the 
maternal mortality and morbidity in California (CMQCC, 2018). CMQCC has published toolkits 
for healthcare professionals to adopt for use in their own facilities. CMQCC has standardized 
care for patients and has provided the information in resources, print and online. This willingness 
to share resources and knowledge is important because the use of standardized policies is 
essential to ensure that mothers are getting proper and timely care (Arora et al., 2016). 
Complications in pregnancy, those situations that lead to maternal mortality and morbidity, may 
occur without any warning. Using evidenced-based protocols can ensure that the women that 
experience a complication are cared for in a manner that improves outcomes (Arora et al., 2016). 
Protocols are very helpful to clinicians because it is a reminder of the baseline expectation for 
providers and of the actions that are expected (Arora et al., 2016). 
Patient Education after Diagnosis 
Nurses are often unprepared to offer self-care education to postpartum mothers upon 
discharge from the hospital (Suplee, Bingham & Kleppel, 2017). Patients may not be receiving 
evidenced-based information and education throughout their stay and at discharge, including the 
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precautions, signs and symptoms of emerging or worsening conditions, and appropriate follow-
up (Suplee, Bingham, & Kleppel, 2017). Since nurses provide a majority of postpartum 
discharge instructions to patients, it is important that nurses are able to give high-quality and 
succinct information to patients that covers any and all key points to reduce maternal mortality 
and morbidity (Suplee, Kleppel, Santa-Donato, & Bingham, 2016). Standardizing the discharge 
teaching for postpartum women has been effective in reducing readmissions and postpartum 
mortality (Bingham, Suplee, Morris, & McBride, 2018). 
3: Project Details 
Design 
The aim of this Doctor of Nursing Practice project was to develop an evidence-based, 
standardized policy and protocol for the care of women with hypertensive disorders of pregnancy 
during intrapartum and postpartum hospital care in a community hospital, including written 
discharge instructions for women diagnosed with hypertensive disorders of pregnancy. This 
protocol will help not only the providers, but also the frontline nurses, in providing timely care to 
patients that present with hypertension in pregnancy. 
Theoretical Framework 
The theoretical framework used for this project was the Iowa model, a framework used 
for implementation of evidenced-based practice that was first introduced in 1994 and has been 
revised since (Titler et al., 2001).  The Iowa model starts with the premise that a change is 
necessary and a priority for the organization (see Figure 2). This model uses triggers, either 
problem- or knowledge-focused, to engage nurses in thinking about ways to improve efficiency 
or effectiveness of care. The model uses a team approach and will be modified slightly for this 
quality improvement project. The first step in the process is to determine a priority topic. A 
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thorough literature review should then be completed to assemble relevant research and related 
literature. Critiquing the research is completed as the project passes through practice committee. 
After the evidenced was critiqued and determined to be sufficient, the protocol was formed, a 
pilot change was implemented and then the protocol is adopted into practice. 
Determine the priority topic Conduct Literature review
Critique and Synthesize
Determine if there is sufficient evidence
Yes No
Conduct EBP 
Project
Conduct Research
Change Pilot AdoptEvaluate
 
Figure 2. Modified IOWA Framework for evidenced based practice. Adapted from Titler et al., 
2001.  
Setting 
The setting for this project was a community hospital in the Southern Johnson County 
area of Kansas that provides intrapartum and postpartum care for women. This hospital has 
approximately 1,400 deliveries per year. The providers that care for these women are a mix of 
obstetricians and family practice physicians. This facility has a Level II NICU that provides care 
for neonates (also called newborns) that are 32 weeks gestation and greater, not requiring a long-
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term ventilator for breathing support. Many women choose the facility they deliver in based on 
the anticipated care for their newborn (March of Dimes, 2015). The implication is that pregnant 
women with moderate risk are seen at this facility. There was no standardized protocol for the 
care of women diagnosed with hypertensive disorders, including preeclampsia, at this facility. 
The care of these women is dependent on nursing knowledge and physician orders. Physician 
preference drives the type of diagnostic evaluation or work-up, use of antihypertensive 
medication, and even how often blood pressure readings were obtained.   
Methodology 
 This project is a quality improvement project for evidenced based practice which is 
defined as a formal and systematic method to improve the processes of a healthcare system 
(Batalden & Davidoff, 2007). The project begins with a matrix review of the literature to 
determine what research pertains to the phenomenon of preeclampsia and medications used in 
the hospital setting. A thorough review of the literature, development of a protocol and 
evaluation of the protocol by an interprofessional team are discussed here. 
Quality Improvement Determination. A determination of quality improvement was 
requested, and approved, for this project from the KUMC Human Subjects 
Committee/Institutional Review Board. The project qualified due to the project evaluating or 
improving the local implementation of widely-accepted clinical or educational standards that 
have been proven effective at other locations.  
 Review of Literature. An initial search using CINAHL, PubMed, MEDline, and Google 
Scholar was performed. The search terms were “maternal mortality and morbidity”, 
“preeclampsia”, “preeclampsia protocol”, “preeclampsia management”, “preeclampsia AND 
protocol”, “preeclampsia AND management”, “clinical practice guidelines”, and “preeclampsia 
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AND clinical practice guidelines”. Inclusion criteria for review included: (a) full-text resources, 
(b) English language, (c) publication within 5 years, and (d) research that focused on protocols 
and guidelines for patients with preeclampsia. Greater attention was given to literature focusing 
on the maternal mortality and morbidity in the United States related to hypertensive disorders in 
pregnancy. A matrix review was created and included as part of the appendices (see Appendix 
A).  
 Research reviewed focuses on several aspects of the preeclamptic patient. In the area of 
medication, there are three medications routinely used for hypertensive emergencies: intravenous 
labetalol, intravenous hydralazine, and oral nifedipine (ACOG, 2013). These medications are 
often studied in research to determine the most efficacious. When reducing blood pressure in a 
pregnant patient, it is important to not reduce too quickly and lead to uteroplacental insufficiency 
(Gavit, Sharma, & Dixit, 2018). Research is split about the most effective medication to reduce 
blood pressure in women with a hypertensive emergency, but all research agrees that the 
difference is minimal. In studies comparing oral nifedipine and intravenous labetalol, oral 
nifedipine was found to be most effective in two studies by lowering the blood pressure the 
quickest (Gavit et al., 2018; Shekar et al., 2013).  In contrast, comparing the two, labetalol has 
been effective with quicker results and less side effects in two studies (Dey et al., 2017; Padmaja 
& Sravanthi, 2017). Two studies found no difference in the efficacy of oral nifedipine and 
intravenous labetalol (Das et al., 2015; Kumari & Srilaxmi, 2016).  Oral nifedipine and 
intravenous hydralazine have also been studied together. Sabir, et al, (2016) found intravenous 
hydralazine to be more effective and Sharma, et al, (2017) found no difference in the efficacy 
two medications.  
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The evidence explains why there are three choices of medication that reduce maternal 
blood pressure in a hypertensive emergency in pregnancy as the efficacy is very similar in all 
medications at reducing the critical blood pressures in pregnant women. Most importantly, early 
intervention, meaning treatment within one hour of confirmed high blood pressure, in the 
reduction of blood pressure is key to reducing maternal morbidity (Shields et al., 2017; Cleary et 
al., 2018). Some of the limitations of the studies include three of the studies were comparative 
studies (Das et al., 2015; Padmaja & Sravanthi, 2017; Sabir et al., 2016), while one was a 
retrospective cohort study (Cleary et al., 2018), and another was an observational study (Gavit et 
al., 2018). Four of the studies were randomized control trials, highly regarded in research (Dey et 
al., 2017; Kumari et al., 2016; Sharma et al., 2017; Shekhar et al., 2013). Inadvertently, research 
shows that using magnesium sulfate with antihypertensive medications is more effective than 
magnesium sulfate alone with a need to treat of 29 to prevent each case of eclampsia (Shields et 
al., 2017). 
Development of Protocol.  A thorough review of the literature related to preeclampsia 
was used to develop an evidenced-based protocol. This protocol was developed with the 
guidance of the toolkit provided by CMQCC (2014) and the recommendations from ACOG 
(2013). These published toolkits are designed for easy modification to fit different facilities 
while keeping patients at the forefront. The maternal early warning signs (MEWS) published by 
National Partnership for Maternal Safety was also used for input for this project (Mhyre et al., 
2014). The MEWS is a tool that has been designed to facilitate initiation of prompt care for 
women who have symptoms related to emergent conditions, including impending 
decompensation or status change.   
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The evidenced-based preeclampsia protocol (see Appendix B) encompasses the care of 
women diagnosed with preeclampsia from initial evaluation through discharge of both pregnant 
and postpartum women. The protocol includes the care of postpartum women  readmitted with 
hypertension or preeclampsia. The preeclampsia protocol also includes the recommended 
discharge instructions, along with teaching, for the women that have been diagnosed with 
preeclampsia during their pregnancy. 
Evaluation of Protocol. After development, the protocol was presented and AGREE II 
instrument, designed by the Appraisal of Guidelines for Research and Evaluation, was shared 
with an interprofessional group of experts, via REDCap. Study data were collected and managed 
using REDCap electronic data capture tools hosted at The University of Kansas.  
The evaluation form consisted of 23 Likert-type statements of agreement (see Appendix 
C) with an area for comments and suggestions with each evaluation statement.  The AGREE II 
instrument is both valid and reliable.  The AGREE II instrument has been used in protocol 
evaluations for clinical guidelines in postpartum women and infants in primary care (Haran et al., 
2014), World Health Organization (WHO) guidelines in maternal health (Polus et al., 2012), and 
clinical practice guidelines for postpartum hemorrhage (Novo et al., 2016). 
The participants included in the REDCap survey were seven OB/GYNs, eight Family 
Practice physicians that have delivery privileges at the hospital, six day shift Registered nurses 
with more than five years of labor and delivery experience, six night shift Registered nurses with 
more than five years labor and delivery experience and the nurse manager of the labor and 
delivery unit.   
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Analysis of Protocol. For the analysis, the Likert-type questions were reviewed to 
determine common levels of agreement amongst participants. The data was analyzed using the 
REDcap system, with descriptive statistics, including mean and range.   
4: Results 
Survey Results 
There were 27 total invitations sent with 15 completed for a 55.6% completion rate. Of 
those invited to the survey, three OB/GYNs, three family medicine physicians and nine 
Registered nurses responded to the survey (see Figure 3).   
          
Figure 3. Breakdown of interprofessional participants, by role, in the preeclampsia protocol 
survey. Adapted from REDCap. 
 
The AGREE II tool is divided into six domains. The first domain focuses on scope and 
purpose. All respondents to the survey answered positively to the overall objective being 
specifically described and the health questions in the guideline being specifically described in the 
protocol. The population to whom the guideline is meant to specifically describe statement 
yielded 86.7% partially agree or strongly agree answers.  
The second domain of the AGREE II tool asks respondents to rate level of agreement 
with statements relating to stakeholder involvement. Of all respondents, 87% either agree or 
0 2 4 6 8 10
Registered Nurse
OB/GYN
Family Medicine
Please indicate your professional role in the 
care of women in labor, delivery, recovery, and 
postpartum:
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strongly agree the protocol includes individuals from all relevant professional groups. The views 
and preferences of the target population being sought was either agreed or strongly agreed by 
80%. Rounding out the second domain, 80% either agreed or strongly agreed that the target users 
of protocol were clearly defined. 
The bulk of the AGREE II tool is in the third domain, which covers statements relating to 
the rigor of development. This domain questions methods, benefits, and updating the protocol. 
Even though 86.7% either agree of strongly agree that systematic methods were used to search 
for evidence only 66.7% either agree or strongly agree that the criteria for selecting the evidence 
was clearly defined and 26.7% of respondents disagree. Of the respondents, 80% either agreed or 
strongly agreed that the strengths and limitations of the body of evidenced were clearly described 
as well as the recommendations were clearly described; however, the other 20% either disagreed 
or were neutral. For the health benefits, side effects, and risks being considered in formulating 
recommendations, 86% either agreed or strongly agreed. The remaining participants were 
neutral. None of the respondents disagreed in any form to a link between the recommendation 
and the supporting evidence and 80% either agreed or strongly agreed to the link. There were 
40% of the participants neutral and 60% that either agreed or strongly agreed that the guideline 
had been externally reviewed by experts prior to its publication.  Even though 40% of 
participants strongly agreed that there is a procedure for updating the protocol, 26.7% disagree. 
The clarity of presentation was the focus of the fourth domain with only three statements.  
All respondents at least partially agreed that the recommendations are specific or unambiguous 
and that the key recommendations are easily identifiable. There was 6.7% of the respondents that 
partially disagreed that the different options for management of the condition or health issue 
were clearly presented but 87% either agreed or strongly agreed to the statement.  
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In the fifth domain, applicability of the protocol was the focus. This domain started with 
a statement about the protocol describing facilitators and barriers to its applications and 20% of 
the respondents either disagreed or partially disagreed, 20% were neutral, and 60% either agreed 
or strongly agreed to the statement. All respondents were either neutral or agreed in some format, 
and over 50% strongly agreed, that the protocol provides advice and/or tools on how the 
recommendations can be put into practice. The potential resource implications of applying 
recommendation have been considered was either agreed or strongly agreed by 80% of the 
respondents. Two respondents disagreed that the protocol presents monitoring and/or auditing 
criteria, while over 73% either agree or strongly agree that the criteria is present in the protocol.  
The final domain had two statements about the editorial independence. Of the responses, 
86.7% either agree or strongly agree that the views of the funding body have not influenced the 
content of the guideline while the other responses were neutral. The final question of the tool 
asked respondents to rate the competing interests of the guideline being recorded and addressed 
and over half of the respondents were neutral and the others either agreed or strongly agreed. 
Respondents were then asked to rate the overall quality of the guideline with a scale 
ranging from one to seven where the “1” is the lowest quality and the “7” is the highest quality, 
26.7% selected a five, 40% selected a six, and 33.3% selected a seven (see Figure 4). 
18 
 
Figure 4. Participant rankings of overall quality of the preeclampsia protocol. Adapted from 
REDCap. 
 
When asked if the participants believe the protocol should be put into use, all respondents 
replied “yes” or “yes with edits” (see Figure 5). 
 
Figure 5. Bar graph of participants response about recommendation for use of the guideline. 
Adapted from REDCap. 
 
All participants had an opportunity for comments, including the following prompts: 
changes they would like to see, what they liked about the protocol, and perceived barriers to 
implementation. Comments regarding suggested improvements to the protocol include one from 
a participant that found an error in the hydralazine algorithm and clarification about who is to 
follow the protocol, physicians or nurses.  Other comments include “great improvement to 
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hospital if approved”, “clear and concise”, “I like the protocol spells out the frequency of the 
assessments needed during the treatment whether IVP, PO or Magnesium. That’s always a 
source of discrepancy from nurse to nurse”, and “I love having the algorithms”. 
Revised Protocol  
After the protocol was created, ACOG released two updated practice bulletins, 
“Gestational Hypertension and Preeclampsia” and “Chronic Hypertension in Pregnancy” 
(ACOG, 2019).  The changes that affect this protocol are the definition of hypertension.  The 
updated definition of hypertension is classified into four categories.  These are normal blood 
pressure which is a systolic blood pressure of 120 mmHg or below and a diastolic blood pressure 
of 80 mmHg or below (ACOG, 2019).  The second category is elevated blood pressure defined 
as systolic blood pressure of 120-129 mmHg and diastolic blood pressure of less than 80 mmHg 
(ACOG, 2019).  The third category is stage 1 hypertension which is systolic blood pressure of 
130-139 mmHg or diastolic blood pressure of 80-89 mmHg (ACOG, 2019). The final category is 
stage 2 hypertension, the definition of systolic blood pressure greater than or equal to 140 mmHg 
or diastolic blood pressure of greater than or equal to 90 mmHg (ACOG, 2019). The change in 
the definition does not change the management in the protocol, but the definition needed to be 
updated in the protocol to remain current. ACOG also describes that the care for patients with 
preeclampsia without severe feature and patients with gestational hypertension are the same so 
there may not be a need for a delineation in the diagnosis given to patient (ACOG, 2019).   
The responses to the survey and the updated information from ACOG were reviewed, and 
necessary changes were made to the protocol after thorough evaluation. The revised protocol 
(see Appendix E) has been forwarded to the OB/PEDS committee and the Nursing Practice 
Council at the community hospital to gain approval for implementation into practice. 
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If approved, the evidence-based protocol would then be forwarded to all physicians by 
the medical staff services department with instructions that the protocol is currently in place.  For 
nursing, the protocol and necessary education would be disseminated during mandatory staff 
meetings and an opportunity for nurses to ask questions and gain clarification. 
Implications for practice  
With the addition of this protocol, care for patients with gestational hypertension and 
preeclampsia will be streamlined. The patients will receive higher quality care because the 
confusion level, and possible errors, will be decreased by nursing staff.  The physicians will have 
a streamlined, evidence-based way to care for patients to ensure that all labs and medications are 
ordered as appropriate for patient condition. For dissemination of this protocol to other facilities 
it would be necessary that it becomes personalized for each facility. It is recommended that 
physicians, providers, and nurses collaborate to ensure that the facilities needs are met with the 
protocol and changes made if needed. 
5: Conclusion 
Early standardized treatment is the necessary change for women with preeclampsia that 
could lessen maternal morbidity and mortality and can positively affect the care given (Shields et 
al., 2017). The developed protocol is research-driven and evidence-based. Providers at this 
community hospital facility will no longer need to be creative in decision-making as they have a 
standardized and evaluated protocol.  The protocol will help the providers develop a plan of care, 
as well as helping the nursing staff with necessary education for patients that have been 
diagnosed with preeclampsia, as there is a lifetime vascular risk in these women (Goynumer et 
al., 2013).  The education component will provide information to women that have been affected 
with preeclampsia about necessary care for a healthier lifetime.   
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Appendix A 
Matrix Review Table 
Author, Title, 
Journal 
Year publication Purpose Methodological 
(study design) 
Young et al., 
“Physicians’ 
knowledge of future 
vascular disease in 
women with 
preeclampsia” 
Hypertension In 
Pregnancy 
2012 Determine the 
knowledge of 
OB/GYNs and 
internists about future 
cardiovascular 
disease in women 
that have had 
preeclampsia 
Anonymous survey 
Goynumer et al., 
“Vascular risk in 
women with a history 
of severe 
preeclmapsia” 
Journal of Clinical 
Ultrasound 
2013 Assess markers of 
vascular dysfunction 
and risk in 
postpartum women 
with a history of 
severe preeclampsia 
Cross-sectional study 
Luo and Ma, “Risk 
factor for 
preeclampsia: a case 
control study” 
Hypertension in 
Pregnancy 
2013 Explore the risk 
factors of 
preeclampsia and 
provide prevention 
information 
Case-control study 
Gulec et al., 
“Comparison of 
clinical and 
laboratory findings in 
early- and late-onset 
preeclampsia” The 
Journal of Maternal-
Fetal & Neonatal 
Medicine 
2013 Comparing the 
clinical findings and 
laboratory results of 
women with onset 
preeclampsia prior to 
34 weeks gestation to 
those with 
preeclampsia onset 
after 34 weeks 
gestation 
Prospective 
longitudinal study 
Brown et al., 
“Women’s perception 
of future risk 
following 
pregnancies 
complicated by 
preeclampsia” 
Hypertension in 
Pregnancy 
2013 Determine what 
women affected by 
preeclampsia 
understand to be their 
future risk of 
cardiovascular 
disease 
Descriptive study 
31 
Koual et al., “Short 
term outcome of 
patients with 
preeclampsia” 
Vascular Health and 
Risk Management 
2013 Evaluate short term 
outcome of women 
affected by 
preeclampsia and 
determine future risk 
of cardiovascular 
disease 
Prospective study 
Shekhar et al., “Oral 
nifedipine or 
intravenous labetalol 
for hypertensive 
emergency in 
pregnancy: A 
randomized 
controlled trial” 
Obstetrics & 
Gynecology 
2013 Compare the 
effectiveness of the 
medications given in 
hypertensive 
emergencies in 
pregnancy to 
determine the best 
medication 
Double-blind 
randomized 
controlled trial 
Pare et al., “Clinical 
risk factors for 
preeclampsia in the 
21st century” 
Obstetrics & 
Gynecology 
2014 Validation of 
previously notated 
clinical risk factors 
for preeclampsia 
Chart Review 
Lisonkova et al., 
“Maternal morbidity 
associated with early-
onset and late-onset 
preeclampsia” 
Obstetrics & 
Gynecology 
2014 Examine trends in 
maternal morbidity 
dependent on timing 
of onset of 
preeclampsia 
Chart Review 
Das et al., 
“Comparative study 
of intravenous 
labetalol and oral 
nifedipine for control 
of blood pressure in 
severe preeclampsia” 
Journal of Dental 
and Medical Sciences 
2015 Determine the best 
medication to control 
blood pressure in 
severe preeclampsia 
Randomized 
controlled trial 
Harris et al., 
“Emergency room 
utilization after 
medically 
complicated 
pregnancies: A 
Medicaid claims 
2015 Determine how many 
women use the 
emergency room after 
pregnancies that have 
had medical 
complications and 
interventions that 
Retrospective 
population based 
cohort study 
32 
analysis” Journal of 
Women’s Health 
may decrease this 
number 
Yamada et al., 
“Isolated gestational 
proteinuria preceding 
the diagnosis of 
preeclampsia- an 
observational study” 
Acta Obstetricia et 
Gynecologica 
Scandanavica 
2015 Determine if isolated 
proteinuria precedes 
the diagnosis of 
preeclampsia 
Observational Study 
Lange et al., 
“Readability, content, 
and quality of online 
patient education 
materials on 
preeclampsia” 
Hypertension in 
Pregnancy 
2015 Evaluation of 
materials about 
preeclampsia found 
online for patient 
education 
Assessment of 
reading materials 
Kilpatrick et al., 
“Severe maternal 
morbidity in a large 
cohort of women 
with acute sever 
intrapartum 
hypertension” 
American Journal of 
Obstetrics and 
Gynecology 
2016 To determine best 
first line treatment 
based on efficacy; 
and determine the 
morbidity and 
mortality of those 
with intrapartum 
severe hypertension 
based on current 
management 
compared to those 
without severe 
hypertension 
intrapartum. 
Retrospective cohort 
study 
Sabir et al., 
“Comparison of oral 
nifedipine with 
intravenous 
hydralazine for acute 
hypertensive 
emergencies of 
pregnancy” Journal 
of Postgraduate 
Medical Institute 
2016 Compare the efficacy 
two of the leading 
medications used to 
treat hypertensive 
emergencies of 
pregnancy 
Comparative study 
Kumari et al., “Oral 
nifedipine versus 
intravenous labetalol 
2016 Compare the efficacy 
of the two 
medications approved 
Randomized trial 
33 
for control of blood 
pressure in severe 
preeclampsia” 
Journal of Evolution 
of Medical and 
Dental Sciences 
to treat severe 
hypertension in 
patients with severe 
preeclampsia. 
Shields et al., “Early 
standardized 
treatment of critical 
blood pressure 
elevations is 
associated with a 
reduction in 
eclampsia and severe 
maternal morbidity” 
American Journal of 
Obstetrics and 
Gynecology 
2017 Determine if 
mortality and 
morbidity is 
improved using a 
standardized 
treatment for severe 
hypertension during 
pregnancy. 
Prospective cohort 
study 
Sharma et al., 
“Hydralazine vs. 
nifedipine for acute 
hypertensive 
emergency in 
pregnancy: A 
randomized 
controlled trial”, 
American Journal of 
Obstetrics and 
Gynecology 
 
2017 Compare the efficacy 
of the two 
medications approved 
to treat severe 
hypertension in 
pregnancy. 
Double-blind 
randomized, 
controlled trial 
Dey et al., 
“Intravenous 
labetalol versus oral 
nifedipine for acute 
blood pressure 
control in severe 
pregnancy-induced 
hypertension- a 
randomized trial” 
Journal of Evolution 
of Medical and 
Dental Sciences 
2017 Compare the efficacy 
of the two 
medications approved 
to lower high blood 
pressure in severe 
pregnancy induced 
hypertension. 
Prospective, 
Interventional, 
Randomized control 
trial 
Padmaja and 
Sravanthi, “A study 
of oral nifedipine and 
intravenous labetalol 
2017 Compare the efficacy 
of the two 
medications approved 
to treat severe 
Randomized trial 
34 
in severe 
hypertension in 
pregnancy at teaching 
hospital” 
International 
Archives of 
Integrative Medicine 
hypertension in 
pregnancy. 
Asgharnia et al., 
“Maternal serum uric 
acid level and 
maternal  and 
neonatal 
complications in 
preeclamptic women: 
A cross-sectional 
study” International 
Journal of 
Reproductive 
Biomedicine 
2017 Determine the 
association between 
the level of uric acid 
in the mother with 
maternal and neonatal 
complications in 
women with 
preeclampsia. 
Cross-sectional study 
Amorim et al., 
“Profile of pregnant 
women with 
preeclampsia” 
Journal of Nursing 
UFPE online 
2017 Describe the clinical 
and socioeconomic 
aspects of women 
with preeclampsia. 
Descriptive and 
Retrospective study 
Gavit et al., “A 
comparative study of 
oral nifedipine and 
intravenous labetalol 
in control of acute 
hypertension in sever 
preeclampsia and 
eclampsia” 
International Journal 
of Reproduction, 
Contraception, 
Obstetrics and 
Gynecology 
2018 Compare the efficacy 
of the two 
medications approved 
to treat severe 
hypertension in 
patients with severe 
preeclampsia and 
eclampsia. 
Comparative study 
Cleary et al., “Use of 
antihypertensive 
medications during 
delivery 
hospitalizations 
complicated by 
preeclampsia” 
2018 Determine the 
amount of use of anti-
hypertensive 
medications used 
during delivery 
hospitalizations for 
preeclampsia. 
Retrospective cohort 
study 
35 
Obstetrics & 
Gynecology 
Mariano et al., 
“Women with 
hypertensive 
syndromes” Journal 
of Nursing UFPE 
online 
2018 Describe the obstetric 
profile of women 
with hypertensive 
syndrome. 
Quantitative, 
exploratory, 
descriptive, 
retrospective, and 
documental study 
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Appendix B 
Protocol: Hypertensive Disorders in Pregnancy 
Purpose of this guideline: 
1. Standardize care of patients with gestational hypertension/preeclampsia 
2. Treatment of critically elevated blood pressure within 1 hour of verification 
3. Use of magnesium sulfate in the presence of critically elevated blood pressures, for seizure 
prophylaxis, regardless if other criteria for preeclampsia are present  
4. Early postpartum follow-up assessment 
Types of Hypertension 
Chronic Hypertension o SBP ≥ 140 or DBP ≥ 90 
o Pre-pregnancy or < 20 weeks gestation 
Gestational Hypertension o SBP ≥ 140 or DBP ≥ 90 
o > 20 weeks gestation 
o Absence of proteinuria or systemic signs/symptoms 
Preeclampsia o SBP ≥ 140 or DBP ≥ 90 
                             -WITH- 
o Proteinuria, or Protein/Creatinine ration of >0.3 mg/dL with or 
without signs/symptoms 
                                -OR- 
o Presentation of signs/symptoms/lab abnormalities but no 
proteinuria 
Chronic Hypertension + 
Superimposed 
Preeclampsia 
 
Preeclampsia with severe 
features 
                        -ANY of the following 
o Two severe BP values (SBP ≥ 160 or DBP ≥ 110) obtained 15-60 
minutes apart 
o Persistent oliguria <500 ml/24 hours 
o Progressive renal insufficiency 
o Unremitting headache/visual disturbances 
o Pulmonary edema 
o Epigastric/RUQ pain 
o LFTs > 2x normal 
o Platelets < 100,000 
o HELLP syndrome 
o Serum Creatinine > 1.1mg/dL 
Adapted from ACOG 2017 
Definitions 
Severe Hypertension 
• Systolic Blood Pressure ≥ 160 or 
• Diastolic Blood Pressure ≥ 110 
Hypertensive Emergency 
• Persistent, severe hypertension that can occur antepartum, intrapartum, or postpartum 
o Defined as: Two severe values (≥ 160/110) taken 15-60 minutes apart, severe values do 
not need to be consecutive 
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If a patient experiences a new onset BP of SBP ≥ 140 or DBP ≥ 90 on two occasions at least 4 hours 
apart (review prenatal record): 
1. Notify provider 
2. Obtain labs 
a. CBC 
b. CMP 
c. UA (consider straight catheterization for postpartum) 
d. Protein/Creatinine ratio 
e. LDH 
f. Uric acid 
3. Assess for severe features of preeclampsia 
a. Headache not relieved by acetaminophen or ibuprofen 
b. Visual disturbances 
c. Altered mental status 
d. Epigastric pain 
e. Pulmonary edema 
f. Shortness of breath 
g. Increased respiratory rate 
h. Deep tendon reflexes 
4. Pad bed rails 
5. Continue BP assessment at least hourly intrapartum and at least every 4 hours postpartum 
Any Two severe BP values (SBP ≥ 160 or DBP ≥ 110) obtained 15-60 minutes apart: 
1. Notify provider 
2. Obtain labs, if not done previously 
a. CBC 
b. CMP 
c. UA (consider straight catheterization for postpartum) 
d. Protein/Creatinine ratio 
e. LDH 
f. Uric acid 
3. Assess for severe features of preeclampsia 
a. Headache not relieved by acetaminophen or ibuprofen 
b. Visual disturbances 
c. Altered mental status 
d. Epigastric pain 
e. Pulmonary edema 
f. Shortness of breath 
g. Increased respiratory rate 
h. Deep tendon reflexes 
4. Obtain order for antihypertensive medication 
a. IV Labetalol 
i. Onset 2-5 minutes, peak 5 minutes 
b. IV Hydralazine 
i. Onset 5-20 minutes, peak15-30 minutes 
c. PO Nifedipine 
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i. Onset 5-20 minutes, peak 30-60 minutes 
5. Once BP in controlled (<160/110), measure: 
a. Every 10 minutes for 1 hour 
b. Every 15 minutes for next hour 
c. Every 30 minutes for next hour 
d. Every hour for 4 hours 
6. Pad bed rails 
7. Consider magnesium sulfate for seizure prophylaxis, continue for 24 hours post delivery 
8. Continue BP assessment at least hourly intrapartum and at least every 4 hours postpartum 
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Nursing Assessment: 
Preeclampsia without Severe Features 
  Antepartum* Intrapartum* Postpartum* 
BP, Pulse, Respiration, SaO2 Every 4 hours Every 60 min Every 4 hours 
Lung Sounds Every 4 hours Every 4 hours Every 4 hours 
Deep Consciousness 
Every 8 hours Every 8 hours Every 8 hours 
Edema 
Assessment for headache, visual 
disturbances, epigastric pain 
Fetal status Every shift Continuous N/A 
Intake and Output Every 1 hour with totals every shift and every 24 hours 
*minimum frequency for the patient NOT on magnesium sulfate 
 
Preeclampsia Intrapartum and Postpartum for Women on Magnesium Sulfate 
BP, Pulse, Respiration, SaO2 • Every 5 minutes during loading dose and every 30 minutes 
during maintenance of magnesium sulfate solution 
• Can change to every 60 minutes if any one or more of the 
following criteria are met: 
o Preeclampsia without severe features 
o BP stable without increases for a minimum of 2 hours 
o No antihypertensives within last 6 hours 
o Antepartum patient 
o Latent phase of labor 
• Continuous SaO2 during magnesium infusion for intrapartum. 
For postpartum patient, check with vital signs 
Lung Sounds Every 2 hours 
Deep tendon reflexes & clonus 
Every 4 hours 
Edema 
Level of consciousness 
Assessment for headache, visual 
disturbances, epigastric pain 
Temperature Per protocol 
Intake and Output Intake: 
• IV solutions and medication drips should all be on a pump 
• Total hourly intake should be ≤ 125 mL/hr 
• NPO with ice chips or as permitted by practitioner 
Output: 
• Insert foley with urometer 
Calculate hourly, end of shift, and 24-hour totals 
Fetal status and uterine activity Continuous fetal monitoring 
Adapted from CMQCC 
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Recommend Discharge Instructions for patients with preeclampsia: 
1. Take BP daily at home 
2. Home Health visit 3-5 days after discharge 
3. Follow-up with provider 7-10 post discharge 
4. Follow-up with General Practitioner within 6-12 months to ensure BP has normalized 
5. Yearly physical including BP, lipid profile, fasting glucose, and BMI 
 
Call your provider immediately if you experience any of the following symptoms: 
A blood pressure reading that is greater than: Systolic 160 or Diastolic 110 
Headaches, not relieved by medication 
Changes in your vision (blurred vision, flashes of light, or spots) 
Upper abdominal pain or tenderness 
Increase in swelling, especially of face 
Change in level of consciousness  
Call 911 if you experience any seizures 
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Labetalol 20mg IV 
over 2 minutes
Repeat 
BP in 10 
minutes
If SBP       or DBP        
administer labetalol 40mg IV 
over 2 minutes, if below 
threshold continue to 
monitor BP closely
Repeat BP in 10 
minutes
Repeat BP in 10 
minutes
If SBP       or DBP   
110  administer 
labetalol 80mg IV over 2 
minutes, if below 
threshold continue to 
monitor BP closely
Repeat BP in 10 
minutes
If SBP       or DBP        
administer hydralizine 10mg 
IV over 2 minutes, if below 
threshold continue to 
monitor BP closely
Repeat BP in 20 
minutes
If SBP       or DBP   
110 at 20 minutes, 
notify physician. Obtain 
emergenccy consult 
from specialists in MFM, 
internal medicine, 
anesthesiology, or 
critical care
Once BP thresholds 
are achieved, 
repeat BP
Give additional 
antihypertensives 
medication per 
specific order as 
recommended by 
specialist
• Every 10 minutes for 1 hour
• Then every 15 minutes for 1 hour
• Then every 30 minutes for 1 hour
• Then every hour for 4 hours
Institute additional 
BP monitoring per 
specific orders
Labetalol Algorithm
 
• Hold IV labetalol for maternal pulse under 60 bpm 
• Maximum cumulative dose of labetalol should not exceed 220mg in 24 hours 
• There may be adverse effects and contraindications. Clinical judgement should prevail 
• Avoid IV labetalol with active asthma, heart disease, or congestive heart failure, use with caution with history of asthma, may cause neonatal bradycardia 
• Active asthma is symptoms at least once per week, use of inhaler or corticosteroids for asthma during the pregnancy, or any history of intubation or hospitalization for 
asthma 
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hydralazine 5mg or 10 
mg IV over 2 minutes
Repeat 
BP in 10 
minutes
If SBP       or DBP        
administer labetalol 10mg IV 
over 2 minutes
Repeat BP in 20 
minutes
Repeat BP in 20 
minutes
If SBP       or DBP   
110  administer 
labetalol 20mg IV over 2 
minutes, if below 
threshold continue to 
monitor BP closely
Repeat BP in 10 
minutes
If SBP       or DBP       at 20 minutes, notify 
physician. Obtain emergenccy consult from specialists 
in MFM, internal medicine, anesthesiology, or critical 
care
Once BP thresholds 
are achieved, 
repeat BP
Give additional 
antihypertensives 
medication per 
specific order as 
recommended by 
specialist
• Every 10 minutes for 1 hour
• Then every 15 minutes for 1 hour
• Then every 30 minutes for 1 hour
• Then every hour for 4 hours
Institute additional 
BP monitoring per 
specific orders
Hydralazine Algorithm
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Oral nifedipine 10 mg
Repeat 
BP in 10 
minutes
If SBP       or DBP        
administer Oral nifedipine 
10 mg, if below threshold 
continue to monitor BP 
closely
Repeat BP in 20 
minutes
Repeat BP in 20 
minutes
Administer round of 
oral nifedipine 20 
mg
If SBP       or DBP       at 20 minutes, notify 
physician. Obtain emergenccy consult from specialists 
in MFM, internal medicine, anesthesiology, or critical 
care
Once BP thresholds 
are achieved, 
repeat BP
Give additional 
antihypertensives 
medication per 
specific order as 
recommended by 
specialist
• Every 10 minutes for 1 hour
• Then every 15 minutes for 1 hour
• Then every 30 minutes for 1 hour
• Then every hour for 4 hours
Institute additional 
BP monitoring per 
specific orders
Oral Nifedipine Algorithm
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Call for help
1. Position patient in left lateral decubitus position
2. Establish open airway and maintain breathing
3. Check Oxygen level
4. Check blood pressure and pulse
5. Obtain IV access: 1 or 2 large bore IV catheters
Magnesium Sulfate 4-6 
gram IV loading dose over 
15-20 minutes; followed 
by a 2 gram/hour 
maintenance dose if renal 
function is normal 
If the patient seizes again while 
on magnesium sulfate 
maintenance dose:
1. Maintain airway and oxygenation
2. Give a 2nd loading dose of magnesium sulfate 2 grams over 5 minutes
3. Observe for signs of magnesium toxicity
If patient has a 
recurrent seizure 
afer 2nd loading 
dose of magnesium 
sulfate, consider the 
following:
1. Midazolam (versed) 1-2 mg IV (can repeat in 5-
10 minutes) OR
2. Lorazepam (ativan) 4mg IV over 2-5 minutes 
(can repeat in 5-15 minutes to a maximum of 8 
mg in 12 hours) OR
3. Diazepam (valium) 5-10 mg IV slowly (can 
repeat 15 minutes up to 30 mg) OR
4. Phenytoin (Dilantin) 1000mg over 20 minutes
5. Monitor respiration and BP, ECG, and signs of 
magnesium toxicity. Phenytoin may cause QRS or 
QT prolongation
Resolution of seizures:
1. Maintain magnesium sulfate 
infusion until 24 hours after the last 
seizure or after delivery, whichever is 
later
2. Assess for neurologic injury/
deficit: head imaging should be 
considered if neurologic injury is 
suspected
3. Once the patient is stabilized 
preparations should be made for 
delivery: mode of delivery is 
dependent upon clinical 
circumstances surrounding 
pregnancy
Discontinuation of therapy:
Severe preeclampsia and eclampsia:
24 hours after delivery or last seizure
NOTE: Administration beyond 24 
hours may be indicated if the patient 
shows no signs of improvement
Eclampsia Algorithm
Adapted from CMQCC, 2013
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Appendix C 
AGREE II Form 
AGREE II INSTRUMENT  AGREE II INSTRUMENT 
DOMAIN 1. SCOPE AND PURPOSE  
  
1. The overall objective(s) of the guideline is (are) specifically described.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
2. The health question(s) covered by the guideline is (are) specifically described.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments   
  
3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically 
described.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
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DOMAIN 2. STAKEHOLDER INVOLVEMENT  
  
4. The guideline development group includes individuals from all relevant professional groups.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
  
5. The views and preferences of the target population (patients, public, etc.) have been sought.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
 Comments   
  
6. The target users of the guideline are clearly defined.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
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DOMAIN 3. RIGOUR OF DEVELOPMENT  
  
7. Systematic methods were used to search for evidence.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
8. The criteria for selecting the evidence are clearly described.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
9. The strength and limitations of the body of evidence are clearly described.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
10. The methods for formulating the recommendations are clearly described.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
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11. The health benefits, side effects, and risks have been considered in formulating the 
recommendations.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
12. There is an explicit link between the recommendations and the supporting evidence.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
  
13. The guideline has been externally reviewed by experts prior to its publication.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
14. A procedure for updating the guideline is provided.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
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DOMAIN 4. CLARITY OF PRESENTATION  
  
15.  The recommendations are specific and unambiguous.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
16. The different options for management of the condition or health issue are clearly presented.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
  
17. Key recommendations are easily identifiable.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
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DOMAIN 5. APPLICABILITY  
  
18. The guideline describes facilitators and barriers to its application.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
19. The guideline provides advice and/or tools on how the recommendations can be put into practice.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
  
20. The potential resource implications of applying the recommendations have been considered.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
  
21. The guideline presents monitoring and/or auditing criteria.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
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DOMAIN 6.  EDITORIAL INDEPENDENCE  
  
22. The views of the funding body have not influenced the content of the guideline.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
23. Competing interests of guideline development group members have been recorded and addressed.  
  
1  
Strongly Disagree  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Strongly Agree  
  
Comments  
  
  
  
   
  
  OVERALL GUIDELINE ASSESSMENT                  
For each question, please choose the response which best characterizes the guideline assessed:  
                                                                                
1. Rate the overall quality of this guideline.  
  
1  
Lowest possible 
quality  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
Highest possible 
quality  
  
2. I would recommend this guideline for use.  
  
YES    
YES, With modifications    
NO    
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NOTES                          
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Appendix D 
Protocol: Hypertensive Disorders in Pregnancy-Revised 
Protocol: Hypertensive Disorders in Pregnancy 
Purpose of this guideline: 
1. Standardize care of patients with gestational hypertension/preeclampsia 
2. Treatment of critically elevated blood pressure within 1 hour of verification 
3. Use of magnesium sulfate in the presence of critically elevated blood pressures, for seizure 
prophylaxis, regardless if other criteria for preeclampsia are present  
4. Early postpartum follow-up assessment 
Types of Hypertension 
Chronic Hypertension o Hypertension diagnosed or present before pregnancy or before 
20 weeks gestation; or hypertension that is diagnosed for the 
first-time during pregnancy and does not resolve in the  
postpartum period  
Gestational Hypertension o SBP ≥ 140 or DBP ≥ 90 
o > 20 weeks gestation 
o Absence of proteinuria or systemic signs/symptoms 
Preeclampsia o SBP ≥ 140 or DBP ≥ 90 
                             -WITH- 
o Proteinuria, or Protein/Creatinine ration of >0.3 mg/dL with or 
without signs/symptoms 
                                -OR- 
o Presentation of signs/symptoms/lab abnormalities but no 
proteinuria 
Chronic Hypertension + 
Superimposed Preeclampsia 
o Preeclampsia in a woman with a history of hypertension before 
pregnancy or before 20 weeks gestation 
Preeclampsia with severe 
features 
                        -ANY of the following 
o Two severe BP values (SBP ≥ 160 or DBP ≥ 110) obtained 15-
60 minutes apart 
o Persistent oliguria <500 ml/24 hours 
o Progressive renal insufficiency 
o Unremitting headache/visual disturbances 
o Pulmonary edema 
o Epigastric/RUQ pain 
o LFTs > 2x normal 
o Platelets < 100,000 
o HELLP syndrome 
o Serum Creatinine > 1.1mg/dL 
Adapted from ACOG 2017 and 2019 
Definitions 
Severe Hypertension 
• Systolic Blood Pressure ≥ 160 or 
• Diastolic Blood Pressure ≥ 110 
Hypertensive Emergency 
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• Persistent, severe hypertension that can occur antepartum, intrapartum, or postpartum 
o Defined as: Two severe values (≥ 160/110) taken 15-60 minutes apart, severe values do 
not need to be consecutive 
If a patient experiences a new onset BP of SBP ≥ 140 or DBP ≥ 90 on two occasions at least 4 hours 
apart (review prenatal record): 
6. Notify provider 
7. Obtain labs 
a. CBC (includes Hgb and platelets) 
b. CMP (includes serum creatinine, AST, and ALT) 
c. UA (consider straight catheterization for postpartum) 
d. Protein/Creatinine ratio 
e. LDH 
f. Uric acid 
8. Assess for severe features of preeclampsia 
a. Headache not relieved by acetaminophen or ibuprofen 
b. Visual disturbances 
c. Altered mental status 
d. Epigastric pain 
e. Pulmonary edema 
f. Shortness of breath 
g. Increased respiratory rate 
h. Deep tendon reflexes 
9. Pad bed rails 
10. Continue BP assessment at least hourly intrapartum and at least every 4 hours postpartum 
Any Two severe BP values (SBP ≥ 160 or DBP ≥ 110) obtained 15-60 minutes apart: 
9. Notify provider 
10. Obtain labs, if not done previously 
a. CBC 
b. CMP 
c. UA (consider straight catheterization for postpartum) 
d. Protein/Creatinine ratio 
e. LDH 
f. Uric acid 
11. Assess for severe features of preeclampsia 
a. Headache not relieved by acetaminophen or ibuprofen 
b. Visual disturbances 
c. Altered mental status 
d. Epigastric pain 
e. Pulmonary edema 
f. Shortness of breath 
g. Increased respiratory rate 
h. Deep tendon reflexes 
12. Obtain order for antihypertensive medication, per provider choice, and refer to algorithm 
a. IV Labetalol 
i. Onset 2-5 minutes, peak 5 minutes 
b. IV Hydralazine 
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i. Onset 5-20 minutes, peak15-30 minutes 
c. PO Nifedipine 
i. Onset 5-20 minutes, peak 30-60 minutes 
13. Pad bed rails 
14. Consider magnesium sulfate for seizure prophylaxis, continue for 24 hours post delivery 
15. Once BP in controlled (<160/110), measure: 
a. Every 10 minutes for 1 hour 
b. Every 15 minutes for next hour 
c. Every 30 minutes for next hour 
d. Every hour for 4 hours 
16. Continue BP assessment at least hourly intrapartum and at least every 4 hours postpartum 
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Nursing Assessment: 
Preeclampsia without Severe Features 
  Antepartum* Intrapartum* Postpartum* 
BP, Pulse, Respiration, SaO2 Every 4 hours Every 60 min Every 4 hours 
Lung Sounds Every 4 hours Every 4 hours Every 4 hours 
Deep Consciousness 
Every 8 hours Every 8 hours Every 8 hours 
Edema 
Assessment for headache, visual 
disturbances, epigastric pain 
Fetal status Every shift Continuous N/A 
Intake and Output Every 1 hour with totals every shift and every 24 hours 
*minimum frequency for the patient NOT on magnesium sulfate 
 
Preeclampsia Intrapartum and Postpartum for Women on Magnesium Sulfate 
BP, Pulse, Respiration, SaO2 • Every 5 minutes during loading dose and every 30 minutes 
during maintenance of magnesium sulfate solution 
• Can change to every 60 minutes if any one or more of the 
following criteria are met: 
o Preeclampsia without severe features 
o BP stable without increases for a minimum of 2 hours 
o No antihypertensives within last 6 hours 
o Antepartum patient 
o Latent phase of labor 
• Continuous SaO2 during magnesium infusion for intrapartum. 
For postpartum patient, check with vital signs 
Lung Sounds Every 2 hours 
Deep tendon reflexes & clonus 
Every 4 hours 
Edema 
Level of consciousness 
Assessment for headache, visual 
disturbances, epigastric pain 
Temperature Per protocol 
Intake and Output Intake: 
• IV solutions and medication drips should all be on a pump 
• Total hourly intake should be ≤ 125 mL/hr 
• NPO with ice chips or as permitted by practitioner 
Output: 
• Insert foley with urometer 
Calculate hourly, end of shift, and 24-hour totals 
Fetal status and uterine activity Continuous fetal monitoring 
Adapted from CMQCC 
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Recommend Discharge Instructions for patients with preeclampsia: 
1. Take BP daily at home 
2. Home Health visit 3-5 days after discharge 
3. Follow-up with provider 7-10 post discharge 
4. Follow-up with General Practitioner within 6-12 months to ensure BP has normalized 
5. Yearly physical including BP, lipid profile, fasting glucose, and BMI 
 
Call your provider immediately if you experience any of the following symptoms: 
A blood pressure reading that is greater than: Systolic 160 or Diastolic 110 
Headaches, not relieved by medication 
Changes in your vision (blurred vision, flashes of light, or spots) 
Upper abdominal pain or tenderness 
Increase in swelling, especially of face 
Change in level of consciousness  
Call 911 if you experience any seizures 
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Administer labetalol 
20 mg IV over 2 
minutes Repeat 
BP in 10 
minutes
If SBP       or DBP        
administer labetalol 40 mg IV 
over 2 minutes, if below 
threshold continue to 
monitor BP closely
Repeat BP in 10 
minutes
Repeat BP in 10 
minutes
If SBP       or DBP   
110  administer 
labetalol 80 mg IV over 
2 minutes, if below 
threshold continue to 
monitor BP closely
Repeat BP in 10 
minutes
If SBP       or DBP        
administer hydralizine 10 mg 
IV over 2 minutes, if below 
threshold continue to 
monitor BP closely
Repeat BP in 20 
minutes
If SBP       or DBP   
110 at 20 minutes, 
notify physician. Obtain 
emergency consult from 
specialist in MFM, 
internal medicine, 
anesthesiology, or 
critical care
Once BP thresholds 
are achieved, 
repeat BP
Give additional 
antihypertensives 
medication per 
specific order as 
recommended by 
specialist
• Every 10 minutes for 1 hour
• Then every 15 minutes for 1 hour
• Then every 30 minutes for 1 hour
• Then every hour for 4 hours
Institute additional 
BP monitoring per 
specific orders
• Hold IV labetalol for maternal pulse under 60 bpm
• Maximum cumulative dose of labetalol should not exceed 220mg in 24 hours
• There may be adverse effects and contraindications. Clinical judgement should prevail
• Avoid IV labetalol with active asthma, heart disease, or congestive heart failure, use with caution with history 
of asthma, may cause neonatal bradycardia
• Active asthma is symptoms at least once per week, use of inhaler or corticosteroids for asthma during the 
pregnancy, or any history of intubation or hospitalization for asthma
Labetalol Algorithm
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Administer 
hydralazine 5mg or 
10 mg IV over 2 
minutes Repeat 
BP in 10 
minutes
If SBP       or DBP        
administer hydralazine 
10mg IV over 2 minutes
Repeat BP in 20 
minutes
Repeat BP in 20 
minutes
If SBP       or DBP   
110  administer 
labetalol 20mg IV over 2 
minutes, if below 
threshold continue to 
monitor BP closely
Repeat BP in 10 
minutes
If SBP       or DBP       at 20 minutes, administer 
labetalol 40 mg IV over 2 minutes, and notify physician. 
Obtain emergenccy consult from specialist in MFM, 
internal medicine, anesthesiology, or critical care
Once BP thresholds 
are achieved, 
repeat BP
Give additional 
antihypertensives 
medication per 
specific order as 
recommended by 
specialist
• Every 10 minutes for 1 hour
• Then every 15 minutes for 1 hour
• Then every 30 minutes for 1 hour
• Then every hour for 4 hours
Institute additional 
BP monitoring per 
specific orders
Hydralazine Algorithm
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Oral nifedipine 10 mg
Repeat 
BP in 10 
minutes
If SBP       or DBP        
administer Oral nifedipine 
10 mg, if below threshold 
continue to monitor BP 
closely
Repeat BP in 20 
minutes
Repeat BP in 20 
minutes
Administer round of 
oral nifedipine 20 
mg
If SBP       or DBP       at 20 minutes, notify 
physician. Obtain emergenccy consult from specialist in 
MFM, internal medicine, anesthesiology, or critical care
Once BP thresholds 
are achieved, 
repeat BP
Give additional 
antihypertensives 
medication per 
specific order as 
recommended by 
specialist
• Every 10 minutes for 1 hour
• Then every 15 minutes for 1 hour
• Then every 30 minutes for 1 hour
• Then every hour for 4 hours
Institute additional 
BP monitoring per 
specific orders
Oral Nifedipine Algorithm
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Call for help
1. Position patient in left lateral decubitus position
2. Establish open airway and maintain breathing
3. Check Oxygen level
4. Check blood pressure and pulse
5. Obtain IV access: 1 or 2 large bore IV catheters
Magnesium Sulfate 4-6 
gram IV loading dose over 
15-20 minutes; followed 
by a 2 gram/hour 
maintenance dose if renal 
function is normal 
If the patient seizes again while 
on magnesium sulfate 
maintenance dose:
1. Maintain airway and oxygenation
2. Give a 2nd loading dose of magnesium sulfate 2 grams over 5 minutes
3. Observe for signs of magnesium toxicity
If patient has a 
recurrent seizure 
afer 2nd loading 
dose of magnesium 
sulfate, consider the 
following:
1. Midazolam (versed) 1-2 mg IV (can repeat in 5-
10 minutes) OR
2. Lorazepam (ativan) 4mg IV over 2-5 minutes 
(can repeat in 5-15 minutes to a maximum of 8 
mg in 12 hours) OR
3. Diazepam (valium) 5-10 mg IV slowly (can 
repeat 15 minutes up to 30 mg) OR
4. Phenytoin (Dilantin) 1000mg over 20 minutes
5. Monitor respiration and BP, ECG, and signs of 
magnesium toxicity. Phenytoin may cause QRS or 
QT prolongation
Resolution of seizures:
1. Maintain magnesium sulfate 
infusion until 24 hours after the last 
seizure or after delivery, whichever is 
later
2. Assess for neurologic injury/
deficit: head imaging should be 
considered if neurologic injury is 
suspected
3. Once the patient is stabilized 
preparations should be made for 
delivery: mode of delivery is 
dependent upon clinical 
circumstances surrounding 
pregnancy
Discontinuation of therapy:
Severe preeclampsia and eclampsia:
24 hours after delivery or last seizure
NOTE: Administration beyond 24 
hours may be indicated if the patient 
shows no signs of improvement
Eclampsia Algorithm
Adapted from CMQCC, 2013
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